Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2

Geraldine Gebhart¹, Patrick Flamen¹, Elisabeth G.E. De Vries², Komal Jhaveri*³, and Zena Wimana*¹

¹Department of Nuclear Medicine, Institut Jules Bordet—Université Libre de Bruxelles (ULB), Brussels, Belgium; ²Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; and ³Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York

Since the approval of trastuzumab, a humanized monoclonal antibody against the extracellular domain of human epidermal growth factor receptor 2 (HER2), 3 other HER2-targeting agents have gained regulatory approval: lapatinib, pertuzumab, and trastuzumab–emtansine. These agents have revolutionized the management of HER2-positive breast cancer, highlighting the concept that targeted therapies are successful when patients exhibit tumor-selective expression of a molecular target—in this case, HER2. However, response prediction and innate or acquired resistance remain serious concerns. Predictive biomarkers of a response—which could help in the selection of patients who might benefit from a selected targeted therapy—are currently lacking. Molecular imaging with anti–HER2 probes allows the noninvasive, whole-body assessment of HER2 tumor burden and has the potential to improve patient selection, optimize the dose and schedule, and rationalize assessment of the response to anti-HER2 therapies. Furthermore, unlike biopsy-based HER2 assessment, this approach can reveal inter- or intratumoral heterogeneity as well as variations in HER2 expression over time. This review summarizes the available literature and the current status of molecular imaging as a tool for the assessment of HER2 (target) expression or the prediction of an early treatment response in early and advanced HER2-positive breast cancer.

Key Words: molecular imaging; breast oncology; PET/CT; SPECT/CT; HER2 imaging; human epidermal growth factor receptor

DOI: 10.2967/jnumed.115.157941

Human epidermal growth factor receptor 2 (HER2) is overexpressed in several cancers, including breast, gastric, ovary, prostate, bladder, and lung cancers, and is a proven therapeutic target in the first 2 tumor types (1,2). In breast cancer (BC), in particular, HER2 overexpression is found in 15%–25% of patients and is associated with a clinically aggressive course. Successful targeting of HER2 with a range of anti-HER2 drugs has resulted in markedly improved patient outcomes in both advanced and early disease settings (3).

However, the presence of a target (in this case, HER2) does not always guarantee benefit from matched targeted therapies because downstream signaling resistance or escape can occur. In HER2-overexpressing BC, it has been estimated that about 50% of patients with metastases do not benefit from anti-HER2 therapies (4), and not a single biomarker for identifying nonresponding patients has yet been validated (5).

Furthermore, there is increasing evidence of temporal and spatial heterogeneity in BC HER2 overexpression. Patients with negative test results at diagnosis can have positive test results later in the disease course and vice versa, a fact that explains why biopsy of metastatic disease is a strong recommendation of many clinical treatment guidelines (6). Heterogeneity in biomarker expression at metastatic sites is only beginning to be recognized, with growing appreciation for molecular imaging.

This article focuses on HER2-positive BC and provides a comprehensive overview of the present and future roles of molecular imaging in improving target mapping, predicting benefit from chemotherapy with or without anti-HER2 drugs, and selecting patients for the targeted delivery of potent cytotoxic agents or therapeutic isotopes.

IMAGING OF HER2 (TARGET) EXPRESSION

In clinical practice, HER2 status is determined by immunohistochemistry (IHC) (usually with an antibody recognizing the intracellular domain of the receptor (7)) or fluorescence in situ hybridization (FISH), mostly from the primary tumor and sometimes from a metastatic lesion. HER2 positivity is defined as an IHC score of 3+ or an IHC score of 2+ with a FISH score of greater than or equal to 2.0 (8).

Bearing in mind the heterogeneity of HER2 expression and the resulting issues with macro- and microsampling of tumor samples, whole-body HER2 imaging could complement current standard approaches. Depending on the desired HER2 imaging technique—SPECT or PET—various isotopes can be used, with the latter modality offering images with higher resolution or sensitivity and allowing quantification.

Imaging can be performed with various targeting molecules, such as antibodies, peptides, small-molecule ligands, and aptamers. A full-length, high-molecular-weight monoclonal antibody (mAb) offers slow blood hepatobiliary clearance. In contrast, its bioengineered derived fragments [Fab fragments, F(ab′)2] and variants (scFv, diabodies, and minibodies) and nontraditional protein scaffolds (Affibody molecules, Nanobodies, and antiocalins) result in faster pharmacokinetics with similar affinity and specificity (9). These low-molecular-weight probes can be radiolabeled with isotopes—such as ⁶⁸Ga, ¹⁸F, ⁶⁴Cu, and ⁷⁶Br—for PET imaging—that have a short half-life, allowing imaging on the day of injection with a low radiation burden. In contrast, when mAbs are radiolabeled with isotopes that

Received Jul. 9, 2015; revision accepted Oct. 9, 2015.
For correspondence or reprints contact: Geraldine Gebhart, Department of Nuclear Medicine, Institut Jules Bordet—Université Libre de Bruxelles (ULB), 121 Boulevard de Waterloo, 1000 Brussels, Belgium.
E-mail: geraldine.gebhart@bordet.be
*Contributed equally to this work.
COPYRIGHT © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
have a longer half-life—such as $^{89}$Zr, $^{124}$I, and $^{86}$Y for PET imaging and $^{111}$In for SPECT imaging—images can be retrieved up to several days after tracer injection, allowing optimal uptake in tumor tissue.

**Preclinical Setting**

Since the introduction of trastuzumab (a humanized mAb against HER2) for the treatment of HER2-positive BC more than a decade ago (4), trastuzumab-based HER2 imaging has received increasing attention, with some modalities reaching a successful transition from the laboratory to the clinic. $^{111}$In-, $^{86}$Y-, and $^{225}$Ac-radiolabeled trastuzumab ($10–12$) was introduced first; $^{89}$Zr-trastuzumab ($13$) was introduced a few years later in human tumor–bearing mice. Specific tracer uptake in HER2 tumor–bearing mice was confirmed with higher resolution and better quantification on $^{89}$Zr-trastuzumab PET images. In addition to high stability and maintenance of affinity, this tracer had the immunoreactivity and internalization properties of trastuzumab, despite the radiolabeling modifications. Furthermore, it was recently demonstrated (14) that trastuzumab-based tracers, such as $^{89}$Zr-trastuzumab, can reveal more than the mere expression of HER2; they can reveal its accessibility. Steric hindrance of mucin MUC4, masking the trastuzumab-binding epitope on HER2, negatively affected $^{89}$Zr-trastuzumab tumor uptake. This effect could be counteracted by supplementation with a mucolytic agent, such as N-acetylcysteine, in patient-derived HER2- and MUC4-overexpressing tumors (JIMT1).

An anti-HER2 mAb introduced later—pertuzumab—was also radiolabeled with $^{111}$In or $^{89}$Zr and was used to successfully image HER2-positive tumor xenografts (15,16).

In addition to mAbs, several reports have demonstrated the usefulness of HER2 imaging with Affibody-based tracers. Interestingly, in a study directly comparing a $^{124}$I-trastuzumab mAb with Affibody $^{124}$I-ZHER2:342, the Affibody showed even higher tumor-to-organ ratios than the mAb because of rapid clearance of radioactivity from blood and normal organs (17).

Several anti-HER2 Affibody molecules have also been labeled with $^{68}$Ga, $^{15}$F, $^{64}$Cu, and $^{11}$C for PET and with $^{99m}$Tc and $^{111}$In for SPECT (18–21). Affibody ABY-002 radiolabeled with $^{111}$In for SPECT as well as with $^{68}$Ga for PET was shown to specifically target HER2-expressing xenografts in vivo with both isotopes, but the pharmacokinetic profile for $^{68}$Ga-radiolabeled ABY-002 was favored (20). Both tracers were investigated further in BC patients (22); the findings were in agreement with the preclinical data.

Furthermore, to guarantee maintenance of the targeting abilities of low-molecular-weight Affibody molecules, Wällberg et al. proposed a Sel-tagging technique enabling site-specific $^{11}$C radiolabeling of anti-HER2 Affibody ZHER2:342, resulting in a molecule with lower kidney retention and an overall absorbed dose comparable to that of $^{68}$Ga-ZHER2:342 (21).

HER2 imaging has also been investigated with even smaller probes, namely Nanobodies (23,24). Many anti-HER2 Nanobodies for the noninvasive imaging of HER2 expression have been proposed (23). Studies with Nanobodies radiolabeled with $^{99m}$Tc (2Rs15dHis6) in mice bearing HER2-positive tumors revealed fast blood clearance, low accumulation in nontarget organs (except the kidneys, which are responsible for tracer clearance), and high concomitant tumor-to-blood and tumor-to-muscle ratios at 1 h after injection (24). PET imaging of HER2 expression with $^{68}$Ga-radiolabeled Nanobodies is currently being evaluated by the same group of researchers (Fig. 1) (25).

In addition to the aforementioned probes, oligonucleotides, RNA, and DNA aptamers were recently introduced. A modified RNA aptamer with HER2-specific targeting was labeled with $^{99m}$Tc and allowed SPECT imaging of HER2 expression (26,27). Another group used $^{64}$Cu-WT4340 for PET imaging of HER2 messenger RNA and also demonstrated its successful use for evaluating the therapeutic efficacy of doxorubicin therapy in immunocompromised mice carrying human HER2–positive BC xenografts (28). These new types of radiotracers have so far been investigated only in preclinical models.

Furthermore, various groups have also investigated the use of HER2 imaging for the evaluation of molecular responses to anti-HER2 therapy (heat shock protein 90 [HSP90] and trastuzumab) in vivo in human tumor xenografts with $^{68}$Ga-labeled F(ab')2-trastuzumab (29), $^{89}$Zr-trastuzumab (30), and $^{18}$F-N-[2-(4-fluorobenzamido)ethyl]maleimide–ZHER2:342 PET/CT (31) and $^{111}$In-pertuzumab SPECT/CT (16). All of these modalities allowed the sensitive detection of HER2 downregulation.

**Clinical Setting**

Table 1 summarizes the results of 7 clinical studies of HER2 imaging in BC patients.

In 2000, a pilot study with 10 HER2-positive metastatic BC patients treated with trastuzumab concluded that $^{111}$In-trastuzumab immunoscintigraphy allowed diagnostic predictions with respect to therapeutic efficacy and cardiotoxicity (32). Others investigating this issue in HER2-positive advanced BC patients before treatment with trastuzumab and paclitaxel (33) reported different results. Indeed, of the 15 patients, only 1 showed myocardial uptake not translating into the development of heart failure.

 Nonetheless, HER2-positive tumors were imaged, albeit with a low detection rate, probably because of the poor resolution of SPECT. Imaging quality was remarkably improved with the introduction of $^{89}$Zr-trastuzumab, allowing PET imaging (13). The best time for the assessment of tracer uptake in metastatic lesions was determined to be 4–5 d after tracer administration. Brain metastases, among other metastatic sites, were also successfully imaged. The study also highlighted the importance of the mass of administered protein, concluding that in trastuzumab-naive patients, a higher mass of (nonradiolabeled) trastuzumab (50 mg) enabled better distribution of the tracer into the metastatic lesions.
<table>
<thead>
<tr>
<th>Type of probe</th>
<th>PET or SPECT probe and dose</th>
<th>Patient population</th>
<th>Optimal timing for imaging</th>
<th>Findings</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intact monoclonal antibodies</td>
<td><strong>Intact</strong></td>
<td><strong>PET or SPECT</strong> probe and dose</td>
<td>Patient population</td>
<td>Optimal timing</td>
<td>Findings</td>
</tr>
<tr>
<td><strong>111In-trastuzumab</strong> (185 MBq) with variable amount of trastuzumab</td>
<td>Advanced disease (n = 10)</td>
<td><strong>Not mentioned</strong></td>
<td>Ability to predict cardiotoxicity and response to trastuzumab</td>
<td>Behr et al. (32) (2000)</td>
<td></td>
</tr>
<tr>
<td><strong>111In-trastuzumab</strong> (100–150 MBq) after first therapeutic dose of trastuzumab</td>
<td>Advanced disease (n = 15)</td>
<td><strong>Up to 7 d after injection</strong></td>
<td>Low tumor detection rate; no ability to predict trastuzumab-induced cardiotoxicity</td>
<td>Perik et al. (33) (2006)</td>
<td></td>
</tr>
<tr>
<td><strong>89Zr-trastuzumab</strong> (37 MBq + either 10 or 50 mg of trastuzumab)</td>
<td>Advanced disease (n = 14), on or off trastuzumab therapy</td>
<td><strong>Day 4 or 5 after injection</strong></td>
<td>Excellent tumor uptake; visualization of metastasis in liver, bone, lungs, and brain; 50 mg of trastuzumab needed if patients were off trastuzumab</td>
<td>Dijkers et al. (13) (2010)</td>
<td></td>
</tr>
<tr>
<td><strong>64Cu-trastuzumab</strong> (130 MBq); no unlabeled trastuzumab</td>
<td>Early and advanced disease (n = 6)</td>
<td><strong>48 h after injection</strong></td>
<td>No “cold” trastuzumab used; suboptimal visualization of liver lesions; primary tumors and brain metastasis seen</td>
<td>Tamura et al. (34) (2013)</td>
<td></td>
</tr>
<tr>
<td><strong>64Cu-trastuzumab</strong> (364–512 MBq); 5 mg of trastuzumab preceded by trastuzumab infusion (45 mg)</td>
<td>Advanced disease (n = 8), off trastuzumab therapy for ≥4 mo</td>
<td><strong>48 h after injection</strong></td>
<td>Mapping of lesions close to that obtained by 18F-FDG PET; some lesions seen only on 64Cu-trastuzumab PET; 45 mg of cold trastuzumab needed</td>
<td>Mortimer et al. (35) (2014)</td>
<td></td>
</tr>
<tr>
<td>Affibody molecules</td>
<td><strong>111In- or 68Ga-labeled ABY-002</strong> (80–90 mg, with activity ranging from 110 to 267 MBq)</td>
<td>Advanced disease (n = 3), on or off trastuzumab therapy</td>
<td><strong>3 h after injection</strong></td>
<td>High rate of detection of known lesion on 18F-FDG PET; high level of liver or kidney uptake is problematic</td>
<td>Baum et al. (22) (2010)</td>
</tr>
<tr>
<td><strong>111In-ABY-025</strong> (100 mg, with mean activity of 142.6 MBq; range, 131–154 MBq)</td>
<td>Advanced disease (n = 7) with 5 HER2-positive and 2 HER2-negative tumors; some on trastuzumab therapy</td>
<td><strong>24 h after injection</strong></td>
<td>Visualization of HER2-positive metastases, including those in liver or brain</td>
<td>Sørensen et al. (36) (2014)</td>
<td></td>
</tr>
</tbody>
</table>
In addition, trastuzumab was also labeled with $^{64}$Cu in studies of both early and advanced HER2-positive BC (34,35). In both studies, the best time for imaging was 48 h after tracer injection. However, the results were different; the coinjection of 45 mg of trastuzumab enabled better visualization of liver metastases (35), whereas the results obtained with the administration of only the radiotracer were suboptimal because of a higher liver background (34). Interestingly, both studies compared $^{64}$Cu-trastuzumab PET/CT with $^{18}$F-FDG PET/CT, with a maximum of 13 d in between, and showed that some lesions could be detected only with $^{64}$Cu-trastuzumab PET/CT.

Apart from HER2-directed antibodies, 2 different Affibody molecules, ABY-002 (22) and ABY-025 (36,37), were labeled with $^{68}$Ga or $^{111}$In and injected into patients with advanced BC. In all of the studies, the radiolabeled Affibody molecules allowed imaging of HER2-positive lesions and even brain metastases (36). In the most recent study, increasing tracer uptake over time allowed discrimination between HER2-positive and HER2-negative lesions on the basis of radiotracer uptake and as confirmed by IHC (37). One issue was that because of the high background uptake of the radiolabeled Affibody molecules in the liver, the HER2 status of lesions in this organ could not be properly assessed.

Furthermore, successive HER2 imaging for different therapies was also studied. In one study, HER2 downregulation in the presence of an HSP90 inhibitor could be monitored through a decrease in $^{89}$Zr-trastuzumab uptake and was correlated with a response by RECIST 1.0 (38). In another study by the same group, trastuzumab combined with paclitaxel treatment led to a 20% decrease in $^{111}$In-trastuzumab tumor uptake. Interestingly, although tumor uptake decreased, HER2 imaging was still achievable, suggesting that sufficient HER2 is constantly available at the tumor cell membrane to bind trastuzumab (39).

Regardless of the aforementioned findings, it is critical to demonstrate that assessing HER2 with molecular imaging in advanced BC has clinical utility. Three prospective clinical trials have been designed to address this important question: 1 study at Institut Jules Bordet (NCT01420146) and 2 studies at the University Medical Center Groningen (NCT01832051 and NCT01957332) (Fig. 2).

**Nonspecific Imaging (With $^{18}$F-FDG PET/CT) to Predict Pathologic Response to Systemic Therapies for Early HER2-Positive BC**

The use of $^{18}$F-FDG tumor uptake as a biomarker for predicting a pathologic response to neoadjuvant treatment has been explored in the preclinical and clinical settings, with conflicting results.

**Preclinical Setting**

Ex vivo results demonstrated that significant changes in $^{18}$F-FDG incorporation with trastuzumab therapy could be assessed (40). Furthermore, in vivo changes in $^{18}$F-FDG tumor uptake after therapy accurately differentiated responding and nonresponding human BC xenografts in athymic mice treated with trastuzumab (41). In contrast, in 2 other studies, $^{18}$F-FDG PET could not show an effect of trastuzumab treatment or of an HSP90 inhibitor in mice implanted with HER2-positive human BC tumors (40,42). Interestingly, Fleming et al. reported conflicting results in the same study and postulated that Akt inhibition and the glucose transport rate interfered with $^{18}$F-FDG incorporation and compromised the ability of $^{18}$F-FDG PET to measure treatment responses (43).

**Clinical Setting**

In women receiving systemic treatment for HER2-positive BC before surgery, the use of early $^{18}$F-FDG PET as a predictor of a pathologic complete response (pCR), a surrogate marker of disease-free survival and overall survival, was explored (44). Table 2 summarizes these studies, which were heterogeneous in terms of types of systemic therapies, timing of $^{18}$F-FDG PET, definition of pCR, and pCR rates. All studies but one (45) showed a correlation between early $^{18}$F-FDG PET/CT results and the probability of reaching a pCR. In the “negative” study, the cohort was small (only 25 patients), $^{18}$F-FDG PET/CT was performed 6–8 wk after the start of treatment with the chemotherapy–trastuzumab combination, and the axillary nodes were not evaluated. Among the “positive” studies, 2 studies opted for the evaluation of a metabolic response after 2 cycles of up-front anthracycline-based chemotherapy given as part of a sequential anthracycline–taxane–trastuzumab regimen (46,47). The other studies scheduled early $^{18}$F-FDG PET/CT up front after 1 or 2 cycles of a taxane- and trastuzumab-based combination (48–50).

Furthermore, the multicenter phase 3 Neoadjuvant Lapatinib or Trastuzumab Treatment Optimization (Neo-ALTTO) study was the only one that explored the predictive value of $^{18}$F-FDG PET/CT for dual anti-HER2 therapy given exclusively during a 6-wk “biologic window” and followed by the addition of paclitaxel (51).

The $^{18}$F-FDG PET/CT parameters found to correlate most strongly with a pCR were either the absolute residual SUV$_{max}$ on early $^{18}$F-FDG PET/CT (46,49) or the change in the SUV$_{max}$ threshold (47,48,50,51).

Of note, a multivariate analysis to assess the independent predictive value of early $^{18}$F-FDG PET/CT was performed in only 3 studies; the predictive value was confirmed in 2 studies (48,49). However, in the study conducted by our group (51), the hormone receptor status of the tumor was the most powerful predictor of a pCR. Furthermore,
the study by Coudert et al. is of particular interest because it investigated the concept of a “response-adapted strategy”—escalating therapy with bevacizumab in patients showing a poor metabolic response on 18F-FDG PET/CT while receiving neoadjuvant trastuzumab and docetaxel. The authors demonstrated that the pCR rate was higher when bevacizumab was added than when the neoadjuvant therapy was unchanged.

Although the aforementioned studies reported encouraging results, the clinical utility of performing an early metabolic assessment during neoadjuvant therapy is far from being validated. The clinical utility of any biomarker assessment requires a demonstration that using the biomarker for treatment decision making improves clinical outcomes. Of note, such a demonstration is the last step of a challenging process of biomarker validation, which also comprises the demonstration of analytic and clinical validity.

Studies larger than the elegant study by Coudert et al. will have to be performed and will involve the collaboration of several centers. Critical will be the use of common standardized PET imaging procedures like those developed by Boellaard et al. for the validation of imaging biomarkers. Such multicenter prospective trials will need to explore and validate all or some of the different image-derived parameters extracted from sequential 18F-FDG PET and thought to be correlated with a pCR. Although a change in the SUVmax, a change in the SUVpeak, and the absolute residual SUVmax are the parameters most frequently used in studies of HER2-positive BC—mainly because of their reproducibility—other parameters, such as tumor lesion glycolysis, have also been assessed. A retrospective study compared variations in the change in the SUVmax, the metabolically active tumor volume, and tumor lesion glycolysis at baseline and after 2 cycles of neoadjuvant chemotherapy.

### TABLE 2

<table>
<thead>
<tr>
<th>Type of systemic therapy</th>
<th>Type of study</th>
<th>Timing of early 18F-FDG PET</th>
<th>pCR rate (%) in breast and lymph nodes</th>
<th>Best predictor of pCR</th>
<th>Confirmation in multivariate analysis</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epirubicin-cyclophosphamide (4 cycles and then docetaxel-trastuzumab)</td>
<td>Single center (n = 30)</td>
<td>After 2 cycles</td>
<td>53</td>
<td>Absolute residual SUVmax at PET 2 of ≤3 (breast or axilla) (AUC, 0.91)</td>
<td>Not done</td>
<td>Groheux et al. (46) (2013)</td>
</tr>
<tr>
<td>Anthracycline (followed by taxane) or taxane + trastuzumab; 6–8 cycles</td>
<td>Single center (n = 14)</td>
<td>After 2 cycles</td>
<td>29</td>
<td>50% change in SUVmax threshold with 100% NPV</td>
<td>Not done</td>
<td>Zucchini et al. (47) (2012)</td>
</tr>
<tr>
<td>Trastuzumab, lapatinib, or their combination (later combined with paclitaxel)</td>
<td>Multicenter (n = 66)</td>
<td>After 2 and 6 wk of biologic therapy</td>
<td>35</td>
<td>Metabolic R (EORTC criteria) had doubling of pCR rate</td>
<td>No (hormone receptor status was strongest predictor)</td>
<td>Gebhart et al. (51) (2013)</td>
</tr>
<tr>
<td>Docetaxel + trastuzumab</td>
<td>Single center (n = 57)</td>
<td>After 1 cycle</td>
<td>44</td>
<td>SUVmax at PET 2 of ≤2.1, with required SUVmax at PET 1 of ≤3.7</td>
<td>Yes</td>
<td>Humbert et al. (49) (2014)</td>
</tr>
<tr>
<td>Paclitaxel + carboplatin + trastuzumab</td>
<td>Single center (n = 25)</td>
<td>After 6–8 wk</td>
<td>60*</td>
<td>18F-FDG PET results not correlated with pCR</td>
<td>Not done</td>
<td>Koolen et al. (45) (2013)</td>
</tr>
<tr>
<td>Trastuzumab + docetaxel, with or without carboplatin</td>
<td>Single center (n = 37)</td>
<td>After 1 cycle</td>
<td>38</td>
<td>≥75% change in SUVmax; pCR accuracy, 76%</td>
<td>Yes</td>
<td>Humbert et al. (48) (2012)</td>
</tr>
<tr>
<td>Trastuzumab + docetaxel in case of poor metabolic response, with or without bevacizumab</td>
<td>Multicenter (n = 142)</td>
<td>After 2 cycles</td>
<td>54 in PET R; 24 in PET NR; 44 in PET NR receiving bevacizumab</td>
<td>≥70% change in SUVmax</td>
<td>Not done</td>
<td>Coudert et al. (50) (2014)</td>
</tr>
</tbody>
</table>

*Evaluated in breast only.

AUC = area under the curve; NPV = negative predictive value; R = responders; EORTC = European Organization for Research and Treatment of Cancer; NR = nonresponders.
of epirubicin plus cyclophosphamide followed by 4 cycles of doce-taxel (plus trastuzumab in cases of HER2-positive BC). The authors concluded that the change in tumor lesion glycolysis was the most accurate parameter for the prediction of a pCR, mainly in estrogen receptor–positive, HER2-negative tumors.

HER2 IMAGING TO PREDICT RESPONSE TO NEW ANTI-HER2 THERAPIES FOR ADVANCED HER2-POSITIVE BC

The first large prospective clinical study aimed at exploring HER2 imaging as a clinically useful predictive biomarker in advanced HER2-positive BC is the ZEPHIR study. This multicenter study of advanced HER2-positive BC (NCT01565200), which is a collaborative effort between Belgian and Dutch centers, aims to prospectively examine the role of pretreatment 

\[ { }^{89} \text{Zr} \] \text{trastuzumab PET/CT (HER2 scan)} and early \n
\[ { }^{18} \text{F} \]-FDG PET/CT (performed just before the second cycle of the antibody–drug conjugate [T-DM1]) in identifying lesions that will not respond to T-DM1. Preliminary data on the patient-based predictive abilities of these 2 PET scans, used alone or in combination, have been presented (55) and are promising. A high negative predictive value (100%) was found for \n
\[ { }^{89} \text{Zr} \]-trastuzumab PET results categorized as “negative” at baseline and an absence of a metabolic response on \n
\[ { }^{18} \text{F} \]-FDG PET/CT after one cycle of T-DM1. Furthermore, this study demonstrated that so-called advanced HER2-positive BC was a highly heterogeneous disease, with approximately one-third of patients showing the absence of HER2-specific targeting in all or most metastatic lesions.

Nonetheless, the determination of “negative” lesions must be made with great caution. False-negative results obtained for HER2 lesions by imaging have been described in patients with a high tumor load (56). This finding was seen in patients with \n
\[ { }^{89} \text{Zr} \]-trastuzumab uptake predominantly in the liver on the HER2 scan and subsequent rapid clearance of the tracer from the circulation. The reiteration of the HER2 scan in the presence of trastuzumab therapy resulted in improved pharmacokinetics and enabled better uptake of the tracer in bone lesions. The ZEPHIR study has been extended, with a requirement for biopsies for “HER2-negative” lesions, with the hope of confirming the initial encouraging results.

HER2-TARGETED THERAPY WITH RADIOACTIVE ANTI-HER2 PROBES

As previously mentioned, anti-HER2 probes have been successfully radio-labeled with various isotopes for diagnostic purposes—with SPECT and PET—as well as for targeted therapies. Radioimmunotherapy (RIT) has been investigated predominantly and extensively with trastuzumab and therapeutic radionuclides, such as β-emitters \n
\[ { }^{177} \text{Lu} \] (57–60), \n
\[ { }^{90} \text{Y} \] (60,61), and \n
\[ { }^{18} \text{Re} \] (62,63); Auger electron emitter \n
\[ { }^{111} \text{In} \] (64); and even α-emitter actinium (12). All showed therapeutic efficacy in HER2-expressing xenografts. In addition, a combination of RIT and radiosensitizing chemotherapy was shown to potentiate the therapeutic effect of \n
\[ { }^{212} \text{Pb} \]-radiolabeled trastuzumab, resulting in prolonged median survival in HER2-positive xenograft models (65). RIT with \n
\[ { }^{90} \text{Y} \]-trastuzumab was even found to be applicable to BC expressing small amounts of HER2 (67). The results obtained with other candidates for RIT, such as the smaller Affibody molecules (66) and Nanobodies (177Lu (67) or \n
\[ { }^{90} \text{Y} \] (68)), have been encouraging. In addition, a first-in-human study assessing the safety of intraperitoneal α-RIT with \n
\[ { }^{212} \text{Pb} \]-TCMC-trastuzumab was presented recently. The latter approach showed an acceptable degree of early toxicity and absence of late toxicity (69).

CONCLUSION AND PERSPECTIVES

HER2 is an important target in the management of BC. Therefore, the assessment of HER2 is an essential step in the diagnostic workup and the selection of optimal treatments in both early-stage and metastatic settings. However, the heterogeneity of the disease, particularly in the metastatic setting, and the limited number of metastases that can be easily accessed for a biopsy remain issues of concern for the clinically available tests (IHC and FISH) with which HER2 status is determined.

Several anti-HER2 probes developed for both SPECT and PET have been proposed since the early 2000s as noninvasive approaches for assessing whole-body HER2 expression patterns, and some probes have successfully reached the clinical setting (Table 1). Small molecules—such as antibody fragments, Affibody molecules, and Nanobodies—offer the advantages of rapid uptake and clearance, uptake in tumors, and a low radiation burden for patients, thus enabling both early (1 h after administration) and serial HER2 imaging. In contrast, mAbs, with their slow clearance, allow for optimal imaging after several days at the cost of a higher radiation burden. Nonetheless, mAbs not only offer the advantage of identifying the presence of HER2 expression but also provide insight on mAb–target interactions, such as target availability or accessibility and complex internalization. These abilities are important for predicting responses to mAb-based treatments because accessibility is dependent on the size of the probe as well as the presence of the binding epitope on the target (14,70).

At present, predicting which type of HER2 tracer will be preferred in the clinical setting is difficult. We propose that the actual indication for HER2 imaging will dictate the choice of the imaging modality. For instance, low-molecular-weight probes could offer an alternative to IHC or FISH for diagnostic purposes or for the prediction of responses to treatment with small molecules (e.g., lapatinib, radiolabeled Nanobodies). In contrast, mAbs might be preferred when the intention is to treat with mAb-based therapies (e.g., trastuzumab, T-DM1, pertuzumab, radiolabeled mAbs). With regard to the recently introduced messenger RNA aptamers, further studies are needed, but these agents might be used to monitor treatment responses.

Of note is the fact that in preclinical models as well as in humans, the amount of protein or peptide influences the in vivo distribution pattern of the tracer (37,56,71). This fact was demonstrated in various studies in which increasing the nonradioactive probe content increased the contrast until a particular “threshold,” beyond which the contrast decreased, was reached. Therefore, the optimal amount of a probe, rather than the maximum obtainable specific activity, should be considered.

\[ { }^{18} \text{F} \]-FDG PET/CT has been used extensively in the neoadjuvant setting as an integrated biomarker to predict a pCR. Although the results have been encouraging, the next step is to establish its value as an integral biomarker that allows treatment deescalation or escalation on the basis of an early metabolic response/nonresponse or a poor response, respectively, as noted on \n
\[ { }^{18} \text{F} \]-FDG PET early after treatment initiation. Given the plethora of anti-HER2 agents that are currently clinically available and the lack of predictive tissue biomarkers beyond HER2, there is certainly a pressing need to demonstrate the clinical utility of noninvasive HER2 imaging or \n
\[ { }^{18} \text{F} \]-FDG PET/CT in advanced disease (e.g., helping to select a subset of patients who might most benefit or not benefit from a particular anti-HER2 therapy).
Molecular imaging has great potential to become a valuable tool in this new era of “personalized and precision medicine.” Important steps in adapting a new “image and treat” strategy in HER2-positive BC have already been accomplished. With additional prospective clinical studies and validation, molecular imaging in HER2-positive BC could allow patient-tailored dosage adaptation, with early cessation of futile (and expensive) therapies and deescalation of “aggressive” treatment, ultimately resulting in cost savings, lower morbidity, and improved patient outcomes.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

REFERENCES


Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2

Geraldine Gebhart, Patrick Flamen, Elisabeth G.E. De Vries, Komal Jhaveri and Zena Wimana

Doi: 10.2967/jnumed.115.157941

This article and updated information are available at:
http://jnm.snmjournals.org/content/57/Supplement_1/81S

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml